I'm not sure if this helps or hinders but I think shareholders should have a look and make an assessment for themselves;
- I've talked about the goodwill on acquisitions before - check out note 12 Intangibles in the annual report p44-45. Radiology Tassie ("RT") for ex, CAJ paid~24.6m (not the full price but close enough) of which 18.5m is goodwill or ~75% of the purchase price.
- For 2018 the RT business made $362k npat on rev of 5.991m - if I extrapolate that for a full year it's about 870k npat on $14.3m Rev. If I use the cost of $24.6m /870k = 28x NPAT paid up front to the vendor with about another 1m due as deferred consideration if whatever hurdles are met
- since year end they bought another $22m of practices, I am pretty sure they have had to draw down on debt to do it as they only had 12m cash at y/e
- it's hard to get clarity on margins etc but the multiples paid seem excessive to me - happy to be shown what I'm missing
Anyway the jury is out for me until we get some clarity in 6 mths or so. Hope it helps. Cheers
- Forums
- ASX - By Stock
- CAJ
- Ann: FY2018 Results Presentation
Ann: FY2018 Results Presentation, page-64
-
- There are more pages in this discussion • 18 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add CAJ (ASX) to my watchlist
(20min delay)
|
|||||
Last
38.0¢ |
Change
0.020(5.56%) |
Mkt cap ! $341.1M |
Open | High | Low | Value | Volume |
36.5¢ | 38.0¢ | 36.5¢ | $366.6K | 980.1K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 1394 | 37.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
38.0¢ | 193185 | 6 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
5 | 335146 | 0.205 |
4 | 294750 | 0.200 |
9 | 662563 | 0.195 |
7 | 1086315 | 0.190 |
4 | 104210 | 0.185 |
Price($) | Vol. | No. |
---|---|---|
0.215 | 360292 | 5 |
0.220 | 318014 | 13 |
0.225 | 188194 | 5 |
0.230 | 1008000 | 2 |
0.235 | 45245 | 2 |
Last trade - 16.10pm 25/11/2024 (20 minute delay) ? |
Featured News
CAJ (ASX) Chart |
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Andy Udell, CCO
Andy Udell
CCO
SPONSORED BY The Market Online